The FDA approved Alcon Laboratories’ travoprost ophthalmic solution 0.004% (Travatan Z) for the reduction of elevated IOP in patients with open-angle glaucoma or ocular hypertension, who are intolerant of, or have insufficient response to other IOP-lowering medication.
Alameda, CA—InSite Vision Inc. submitted a New Drug Application (NDA) to the FDA for a topical 1% azithromycin formulation (Aza-Site) for the treatment of bacterial conjunctivitis.
With the FDA approval of WaveLight AG's wavefront-guided LASIK treatment using the Allegro Analyzer for wavefront analysis in conjunction with the company's 200-Hz Allegretto Wave excimer laser, U.S. refractive surgeons now have another choice for their patients. The indication is for the reduction or elimination of up to –7 D of spherical equivalent myopia or myopia with astigmatism, with up to –7 D of spherical component and up to 3 D of astigmatic component at the spectacle plane.
Madison, WI—Results from a recent study have shown for the first time the potential of anti-vascular endothelial growth factor (VEGF) therapy to improve features of diabetic retinopathy, according to Micheal M. Altaweel, MD.
Las Vegas—Bausch & Lomb has received U.S. FDA approval to add a cold oxygen plasma treatment to the manufacturing process of gas-permeable (GP) contact lenses made with Boston materials. B&L made the announcement recently at the American Optometric Association Congress and Annual American Optometric Student Association Conference.
Santa Ana, CA—Advanced Medical Optics Inc. (AMO) has signed an agreement to sell the rights to six over-the-counter (OTC) eye-care products and the Lens Plus trade name to Inyx Inc., a New York-based specialty pharmaceutical company. The acquisition was expected to close last month.
A number of studies have been conducted and presented during a free paper session, supporting Alcon's research into its investigational AcrySof angle-supported phakic intraocular lens (IOL).
The FDA sent an approval letter to Eli Lilly and Co. for ruboxistaurin mesylate (Arxxant), an investigational oral therapy for the treatment of diabetic retinopathy.
The FDA approved WaveLight’s wavefront-guided procedure, a LASIK treatment approach that combines the Allegro Analyzer with the 200-Hz Allegretto Wave excimer laser.
Athenagen Inc. began a phase I clinical trial of mecamylamine (ATG003), its eye drop therapy for age-related macular degeneration (AMD). Animal models showed efficacy of ATG003 as an alternative to current AMD therapies, which require needle injections directly in the eye. The randomized, placebo-controlled, ascending dose clinical trial is designed to evaluate ocular tolerability and safety for up to 14 days.